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Introduction: Osteoporosis is a disease characterized by low bone mineral density (BMD) and increased risk of
fractures. Studies have demonstrated the use of phytoestrogens, or plant-derived estrogens, such as genistein and
daidzein, to effectively increase osteogenic activity of bone marrow-derived mesenchymal stem cells (BMSCs).
Herein, the effects of daidzein analogs on the osteogenic differentiation efficiency of human BMSC and adipose-derived
stromal/stem cells (ASC) were explored.
Methods: BMSCs and ASCs underwent osteogenic differentiation in the presence of vehicle, 17β-estradiol (E2),
phytoestrogens, or daidzein analogs. Cells were stained for alkaline phosphatase (ALP) enzymatic activity, calcium
deposition by alizarin red s, and phosphate mineralization by silver nitrate. Gene expression analysis was
conducted on cells treated with daidzein analogs.
Results: Cells treated with E2, daidzein, or genistein increased calcium deposition by 1.6-, 1.5-, and 1.4-fold,
respectively, relative to vehicle-treated BMSCs and 1.6-, 1.7-, and 1.4-fold relative to vehicle-treated ASCs, respectively.
BMSCs treated with daidzein analog 2c, 2g, and 2l demonstrated a 1.6-, 1.6-, and 1.9-fold increase in calcium deposition
relative to vehicle-treated BMSCs, respectively, while ASCs treated with daidzein analog 2c, 2g, or 2l demonstrated a
1.7-, 2.0-, and 2.2-fold increase in calcium deposition relative to vehicle-treated ASCs, respectively. Additional analysis
with BMSCs and ASCs was conducted in the more efficient compounds: 2g and 2l. ALP activity and phosphate
mineralization was increased in 2g- and 2l-treated cells. The analysis of lineage specific gene expression demonstrated
increased expression of key osteogenic genes (RUNX2, c-FOS, SPARC, DLX5, SPP1, COL1A1, IGF1, SOST, and DMP1) and
earlier induction of these lineage specific genes, following treatment with 2g or 2l, relative to vehicle-treated cells.
Estrogen receptor (ER) inhibitor studies demonstrated that ER antagonist fulvestrant inhibited the osteogenic
differentiation of 2g in BMSCs and ASCs, while fulvestrant only attenuated the effects of 2l, suggesting that 2l acts
by both ER dependent and independent pathways.
Conclusions: These studies provide support for exploring the therapeutic efficacy of daidzein derivatives for the
treatment of osteoporosis. Furthermore, the patterns of gene induction differed following treatment with each
daidzein analog, suggesting that these daidzein analogs activate distinct ER and non-ER pathways to induce
differentiation in BMSCs and ASCs.* Correspondence: bbunell@tulane.edu
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Osteoporosis is a pathological condition associated with
bone degeneration and is characterized by low bone
mineral density (BMD) and alterations to the architec-
ture of the bone. The low bone density and compro-
mised architecture results in reduced bone strength and
increased susceptibility to fractures, leading to signifi-
cant morbidity and mortality [1-3]. While many factors
contribute to the development of osteoporosis, age will
probably be the leading risk factor due to the aging
population in the United States [4]. It is estimated that
more than 2 million people suffer from osteoporosis at a
cost of $17 billion annually in the United States [5]. Al-
though increasing physical activity is a modifiable lifestyle
choice that can reduce the incidence of osteoporosis [6],
the development of novel therapeutic interventions will
further reduce the development of osteoporosis by sup-
porting healthier bones over an individual’s lifetime.
Current treatment regimens for osteoporosis target
bone regeneration or bone resorption, as these two pro-
cesses are normally balanced in order to maintain strong,
healthy bones. As such, therapeutic compounds have been
divided into two groups: anti-resorptive drugs and ana-
bolic drugs. Anti-resorptive drugs reduce the breakdown
of bone during normal remodeling and reduce bone loss
by limiting osteoclast activity [7]. These drugs include bis-
phosphonate, calcitonin, and denosumab. Studies have
shown that delivery of these drugs independently or in
combination is effective in reducing bone loss. While
these drugs limit the severity of osteoporosis, it is still
necessary for bone to undergo regeneration to restore
the architecture of the bone and provide strength to
the bones. Anabolic drugs have been shown not only to
achieve higher BMD, but also to improve the quality
and the strength of the bone [8].
Estrogens have anti-resorptive activity and anabolic ac-
tivity, which have made them useful for the treatment of
osteoporosis in postmenopausal women [9,10]. However,
the precise mechanism by which this occurs remains to
be determined. Furthermore, while estrogens are consid-
ered powerful modulators of bone metabolism by re-
ducing the development of osteoporosis and increasing
BMD, their use in the form of hormone replacement
therapy has been halted due to its association with an
increased risk of developing breast and endometrial
cancer [11-13]. Effective alternatives to estrogens are
therefore necessary. Raloxifene, a selective estrogen recep-
tor (ER) modulator, has been shown to produce estrogen-
agonistic effects on bone and estrogen-antagonistic effects
on uterine, endometrium, and breast tissue [14]. However,
raloxifene has also been associated with increased risk
of thromboembolic events [15]. There thus remains a
need to identify superior pharmacological therapies to
treat osteoporosis.Plant-derived estrogens, or phytoestrogens, have gained
significant attention and interest because these com-
pounds have been shown to increase osteogenesis with-
out increasing the risk of developing cancer [16-18].
More specifically, phytoestrogens isolated from soy,
namely genistein and daidzein, are able to inhibit the
bone resorption activity of osteoclasts while simultan-
eously stimulating osteogenic differentiation and matur-
ation of bone marrow-derived mesenchymal stem cells
(BMSCs) and osteoblasts [19]. In addition, previous
studies have shown that these compounds have the ability
to induce osteogenesis in osteoporosis-induced ovariecto-
mized animal models [20].
While these studies are encouraging, the osteogenic
potential of these phytoestrogens is less potent than the
estrogens. Developing compounds with increased osteo-
genic potential without the tumorigenic potential of estro-
gens therefore remains a priority. Previously, our group
designed and synthesized daidzein analogs that exhibited
a wide range of estrogenic, anti-estrogenic, and osteogenic
activity [21,22]. Herein, the impact of these daidzein ana-
logs on the osteogenic potential of human BMSCs and
adipose derived stromal/stem cells (ASCs) is described.
Although previous studies have focused on BMSCs as the
precursor to osteoblasts, recent studies have shown that
ASCs differentiate into osteoblasts [23,24]. Additionally,
the ease in isolation of ASCs and their abundance from
adipose tissue makes them ideal candidates for tissue en-
gineering and regenerative purposes.
To characterize the effect of these daidzein analogs
(2c, 2g, and 2l) on BMSCs and ASCs, treated cells were
assessed for the amount of calcium deposition by alizarin
red staining, alkaline phosphatase (ALP) activity by
5-bromo-4-chloro-3-indolyl phosphate (BCIP/NBT)
staining, and phosphate mineralization by silver nitrate
staining. Furthermore, the dose of these compounds ne-
cessary to elicit 50% of the maximal osteogenic effect
(EC50) on BMSCs and ASCs was identified and their ef-
ficacy and potency was compared with 17β-estradiol
(E2). To determine the downstream targets of these
compounds, mRNA expression analysis was conducted
on key osteogenic factors. Together, these studies pro-
vide support for daidzein analogs as novel therapeutic
compounds that have the potential to reduce osteopor-





90-PeCy5, anti-CD34-phycoerythrin, isotype control
fluorescein isothiocyanate human IgG1, and isotype-
control phycoerythrin human IgG2a were purchased
from Beckman Coulter (Indianapolis, IN, USA). Anti-
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ences (San Jose, CA, USA). Type 1 collagenase, bovine
serum albumin (fraction V), calcium chloride, dexa-
methasone, isobuytlmethylxanthine, indomethacin, as-
corbate 2-phosphate, β-glycerol phosphate, alizarin red
S, oil red O, cetylpyridinium chloride, BCIP/NBT, silver
nitrate, E2, daidzein, and genistein were purchased from
Sigma (St Louis, MO, USA). Daidzein analogs (i.e. 2c, 2g,
and 2l) were synthesized in our laboratory as described
previously [21,22].
Human subjects
Primary human BMSCs were obtained from six healthy
consenting Caucasian female donors under a protocol ap-
proved by Tulane University Institutional Review Board.
The cells were prepared from bone marrow aspirates taken
from the iliac crest of six individuals. Nucleated cells were
isolated using Ficoll-Paque density gradient (Amersham
Pharmacia Biotech, Milwaukee, WI, USA) and resus-
pended in complete culture media (CCM), which consisted
of α-Minimal Essential Medium (Gibco, Grand Island,
NY, USA), 20% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA, USA), 100 units/ml penicillin/
100 μg/ml streptomycin (Gibco), and 2 mML-glutamine
(Gibco). The cells were then seeded on a 150 cm2 culture
dish (Nunc, Rochester, NY, USA) and maintained in a
humidified 5% carbon dioxide (CO2) incubator at 37°C.
Medium was changed every 3 to 4 day. When the cultures
reached 70% confluence, the cells were harvested with 0.25%
trypsin/1 mM ethylenediamine tetraacetic acid (EDTA;
Gibco) and cryopreserved prior to experimental use.
Primary human ASCs were obtained from six healthy
consenting Caucasian female donors undergoing elective
liposuction procedures under a protocol approved by
Pennington Biomedical Research Center Institutional
Review Board. ASCs were isolated from processed
lipoaspirates from the subcutaneous adipose tissue of
subjects. Lipoaspirates were incubated in 0.1% type I
collagenase and 1% bovine serum albumin dissolved in
100 ml phosphate-buffered saline (PBS) supplemented
with 2 mM calcium chloride. The mixture was placed
in a 37°C shaking water bath at 75 rpm for 60 minutes
and then centrifuged to remove oil, fat, primary adipo-
cytes, and collagenase solution, leaving behind a pellet
of cells. Cells were resuspended in CCM, plated on
150 cm2 culture dishes, and maintained in a humidified
5% CO2 incubator. Fresh medium was added every 2 to
3 days until cells achieved 80 to 90% confluence and
were harvested with 0.25% trypsin/1 mM EDTA and
cryopreserved prior to experimental use.
Cell culture
Frozen vials of approximately 106 BMSCs or ASCs were
thawed, plated onto 150 cm2 culture dishes (Nunc) in20 ml CCM and incubated at 37°C with 5% humidified
CO2. After 24 hours, medium was removed and adherent,
viable cells were washed with PBS, harvested with 0.25%
trypsin/1 mM EDTA (Gibco), and replated at 100 cells/cm2
in CCM. Medium was replaced every 3 to 4 days. For all
experiments, subconfluent cells (<70% confluence) be-
tween passages 2 and 6 were used.
Flow cytometry
BMSCs and ASCs were harvested with 0.25% trypsin/
1 mM EDTA for 3 to 4 minutes at 37°C. A total of 3 ×
105 cells were suspended in 50 μl PBS and incubated
with fluorescence-labeled primary antibodies. The sam-
ples were incubated for 30 minutes at room temperature
and washed with PBS. The samples were then analyzed
with Galios Flow Cytometer (Beckman Coulter, Brea,
CA, USA) running Kaluza software (Beckman Coulter).
To assay cells by forward and side scatter, FACScan was
standardized with microbeads (Dynosphere uniform mi-
crospheres; Bangs Laboratories Inc., Thermo Scientific,
Waltham, MA, USA). At least 10,000 events were ana-
lyzed and compared with isotype controls.
Colony-forming unit assay
BMSCs and ASCs were plated at a density of 100 cells
on a 10 cm2 plate in CCM and incubated for 14 days.
Plates were then rinsed with PBS and stained with 3%
crystal violet (Sigma) for 30 minutes at room temperature.
Plates were washed with PBS and once with tap water.




BMSCs and ASCs were cultured in six-well plates in
CCM until 70% confluence. Medium was replaced with
fresh osteogenic differentiation medium (ODM) consist-
ing of 50 μM ascorbate 2-phosphate, 10 mM β-glycerol
phosphate, and 10 nM dexamethasone. Where indicated,
the fetal bovine serum in ODM was substituted for char-
coal dextran-stripped fetal bovine serum (charcoal dextran-
stripped osteogenic differentiation medium (CDS-ODM);
Atlanta Biologicals).
Adipogenic differentiation
BMSCs and ASCs were cultured in six-well plates in CCM
until 70% confluence. Medium was replaced with fresh adi-
pogenic induction media made with CCM supplemented
with 0.5 μM dexamethasone, 0.5 mM isobuytlmethyl-
xanthine, and 50 μM indomethacin. Where indicated, the
fetal bovine serum in adipogenic differentiation medium
was substituted for charcoal dextran-stripped adipogenic
differentiation medium (CDS-ADM).
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BMSCs and ASCs were plated in CCM and allowed to
adhere to plastic. The medium was replaced with CDS-
ODM or CDS-ADM and supplemented with vehicle,
10 nM E2, 1 μM daidzein, 1 μM genistein, or 1 μM daid-
zein analog 2c, 2g, or 2l for 14 days. Furthermore, where
indicated, cells were treated with CDS-ODM and supple-
mented with log-fold increases of E2, daidzein, or daidzein
analog from 100 pM to 1 mM. ER antagonist studies were
conducted by concurrent treatment with 100 nM fulves-
trant (ICI187,280; Sigma) and vehicle, 10 nM E2, 1 μM
daidzein, or 1 μM daidzein analog 2g or 2l in CDS-ODM.
Staining and quantification protocols
Alizarin red staining and quantification
After 14 days, cells undergoing osteogenic differentiation
in ODM or CDS-ODM were fixed in 10% formalin for
1 hour, washed with distilled water, and stained with 1%
alizarin red (pH 4.1) to visualize calcium deposition in
the extracellular matrix as a marker of early osteogenesis.
Images were acquired at 4× magnification on a Nikon
Eclipse TE200 with a Nikon Digital Camera DXM1200F
using Nikon ACT-1 software (Melville, NY, USA). For
quantification, alizarin red was extracted from each well
with 10% cetylpyridinium chloride and read at 584 nm
(FLUOstar optima; BMG Labtech, Durham, NC ). To
normalize to the amount of protein in each sample, pro-
tein extraction with RIPA buffer (Pierce, Thermo Scien-
tific) and protein quantification with the BCA assay
(Thermo Scientific) were performed according to manu-
facturer’s instructions.
Oil Red O staining and quantification
After 14 days, cells undergoing adipogenic differentiation
in adipogenic differentiation medium or CDS-ADM were
fixed in 10% formalin for 1 hour, and stained with oil red
O, composed of two parts PBS and three parts 0.5% oil
red O stock solution to visualize neutral lipids. Images
were acquired at 10× magnification on a Nikon Eclipse
TE200 with a Nikon Digital Camera DXM1200F using the
Nikon ACT-1 software. For quantification, oil red O was
extracted from each well with isopropanol and read at
544 nm (FLUOstar optima). To normalize to the amount
of protein in each sample, protein extraction with RIPA
buffer (Pierce, Thermo Scientific) and protein quantifica-
tion with the BCA assay (Thermo Scientific) were per-
formed according to manufacturer’s instructions.
BCIP/NBT staining
After 3 days, cells undergoing osteogenic differentiation
in CDS-ODM were fixed in 10% formalin for 1 hour,
washed with distilled water, and incubated in BCIP/NBT
to visualize ALP activity. Images were acquired at 4×magnification on a Nikon Eclipse TE200 with a Nikon
Digital Camera DXM1200F using Nikon ACT-1 software.
Silver nitrate staining
After 14 days, cells undergoing osteogenic differentiation
in CDS-ODM were fixed in 10% formalin for 1 hour,
washed with distilled water, and incubated in 3% silver
nitrate to visualize phosphate mineralization in the
extracellular matrix as a late marker of osteogenesis. Im-
ages were acquired at 4× magnification on a Nikon
Eclipse TE200 with a Nikon Digital Camera DXM1200F
using Nikon ACT-1 software.
MTT assay
Assessment of cell viability was performed with the MTT
assay. BMSCs and ASCs were plated in triplicate in 96-
well plates (500 cells/well) in CCM supplemented with
vehicle, daidzein analog 2g, or daidzein analog 2l. After
7 and 14 days, cells were incubated with 10 mM MTT
(Invitrogen, Grand Island, NY, USA) for 4 hours at 37°C
with 5% humidified CO2. A total of 100 μl dissolving so-
lution (10% SDS, 0.01 M HCl) was added to each well
and incubated for 12 to 16 hours at 37°C. Absorbance
was measured at 544 nm (FLUOstar optima).
RNA isolation, cDNA synthesis, quantitative reverse
transcription polymerase chain reaction
Cells treated with vehicle, 10 nM E2, 1 μM daidzein, or
1 μM daidzein analog in CDS-ODM were collected on
days 3, 7, and 14. Where indicated, BMSCs and ASCs
treated with vehicle, E2, daidzein, or daidzein analog were
simultaneously treated with 100 nM fulvestrant and col-
lected on days 3, 7, and 14. Total cellular RNA was ex-
tracted from BMSCs and ASCs using the RNeasy Mini Kit
(Qiagen, Valencia, CA, USA), purified with DNase I diges-
tion (Invitrogen) according to the manufacturer’s instruc-
tions, and reverse transcribed using the SuperScript VILO
cDNA synthesis kit (Invitrogen). Quantitative real-time
polymerase chain reaction was performed using the
EXPRESS SYBR GreenER qPCR SuperMix Kit (Invitrogen)
according to the manufacturer’s instructions. The following
forward and reverse primer sequences were used to detect
changes in gene expression: runt-related transcription
factor 2 (RUNX2), 5′-CTCACTACCACACCTACCTG-3′
and 5′-TCAATATGGTCGCCAAACAGATTC-3′; FBJ
murine osteosarcoma viral oncogene homolog (c-Fos),
5′-CCTGTCAAGAGCATCAGCAG-3′ and 5′-GTCAG
AGGAAGGCTCATTGC-5′; osteonectin (SPARC), 5′-TG
TGGGAGCTAATCCTGTCC-3′ and 5′-TCAGGACGTT
CTTGAGCCAGT-3′; distal-less homeobox 5 (DLX5),
5′-TGGCCCGAGTCTTCAGCTAC′ and 5′-TGGTTGG
TCGGTCTCTTTCT-3′; secreted phosphoprotein 1 (SPP1),
5′-GCTCTAGAATGAGAATTGCACTG-3′ and 5′-TGT
CGGTCCTGAGGTAACTG-3′; collagen type 1 alpha
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5′-AGGTGATTGGTGGGATGTCTT-3′; insulin-like growth
factor 1 (IGF1), 5′-CTGTGATCTAAGGAGGCTG-3′
and 5′-TTCGTGTTCTTGTTGGTAGA-3′; dentin matrix
acidic phosphoprotein 1 (DMP1), 5′-GTGAGTGAGTC
CAGGGGAGATAA-3′ and 5′-TTTTGAGTGGGAGAG
TGTGTGC-3′; sclerostin (SOST), 5′-TCCCCACCACC
CCTTTG-3′ and 5′-GGTCACGTAGCGGGTGAA-3′;
and β-actin, 5′-CACCTTCTACAATGAGCTGC-3′
and 3′-TCTTCTCGATGCTCGACGGA-3′. All reverse
transcription-polymerase chain reaction primers were
designed using Primer3 (Free Software Foundation
Inc.,Boston, MA, USA) and purchased from Integrated
DNA Technologies (Coralville, IA, USA). The expression
of human β-actin was used to normalize the mRNA con-
tent. Samples were tested in triplicate. No-template con-
trols and no-reverse transcription controls were included
in each polymerase chain reaction run.
Statistical analysis
All values are presented as the mean ± standard devi-
ation. Experiments were conducted separately with each
donor, plated in triplicates for technical duplicates. The
values for the technical duplicates for each donor were
averaged together. The values for the six donors were
averaged together to calculate the mean ± standard devi-
ation. The statistical differences between two or more
groups were determined by analysis of variance, followed
by post hoc Bonferroni multiple comparison tests. Statis-
tical significant was set at P < 0.05. Only statistically sig-
nificant values were considered relevant. Analysis was
performed using Prism (Graphpad Software, San Diego,
CA, USA).
Results
BMSCs and ASCs demonstrate similar stem cell
characteristics
BMSCs and ASCs were stained for cell surface antigens,
plated for colony-forming units, and induced to differen-
tiate down osteogenic and adipogenic lineages. BMSCs
and ASCs displayed overlapping cell surface marker pro-
files (CD44+, CD90+, CD105+, CD166+, CD11b−, CD34−,
and CD45−), were able to form colony-forming units,
and underwent osteogenic and adipogenic differentiation
(Additional file 1).
Phytoestrogens enhance osteogenic differentiation while
only estradiol enhanced adipogenic differentiation of
BMSCs and ASCs
BMSCs and ASCs were cultured in CDS-ODM and sup-
plemented with vehicle, E2, daidzein, or genistein. After
14 days, cells were stained with alizarin red and imaged
with bright-field microscopy (Figure 1A). Alizarin red
staining was quantified by eluting the alizarin red stainingand acquiring optical density measurements. E2-treated,
daidzein-treated, and genistein-treated BMSCs demon-
strated 1.6-fold, 1.5-fold, and 1.4-fold greater osteogenic
differentiation compared with vehicle-treated BMSCs, re-
spectively (P < 0.01; Figure 1B). ASCs treated with E2,
daidzein, and genistein demonstrated a 1.6-fold, 1.7-fold,
and 1.4-fold increase in osteogenic differentiation relative
to vehicle-treated ASCs (normalized to 1.0), respectively
(P < 0.01; Figure 1B). It should be noted that while E2,
daidzein, and genistein all enhanced osteogenic differenti-
ation on average, two of the six BMSC donors and three
of the six ASC donors did not respond to genistein
treatment. Furthermore, visualization with bright-field
microscopy did not demonstrate enhanced cell death
in genistein-treated BMSCs or ASCs, compared with
vehicle-treated cells.
To determine the effect of E2 or phytoestrogens on
adipogenic differentiation of BMSCs and ASCs, cells
were cultured in CDS-ADM and supplemented with E2,
daidzein, and genistein. After 14 days, cells were stained
with oil red O and imaged with bright-field microscopy
(Figure 1C). Oil red staining was quantified by eluting
with isopropanol and measuring the optical density of
the extracted product. E2-treated BMSCs and ASCs dem-
onstrated enhanced adipogenic differentiation by 1.6-fold
compared with vehicle-treated BMSCs and ASCs (P < 0.01;
Figure 1D). Daidzein enhanced adipogenic differentiation
of BMSCs by 1.2-fold compared with vehicle-treated
BMSCs (P < 0.01; Figure 1D) but had no effect on the adi-
pogenic differentiation of ASCs. Genistein also had no ef-
fect on the adipogenic differentiation of BMSCs or ASCs.
Daidzein analogs enhance osteogenic differentiation
while reducing adipogenic differentiation of BMSCs
and ASCs
To determine the osteogenic potential of daidzein ana-
logs on BMSCs and ASCs, daidzein analogs 2c, 2g, and
2l were supplemented into CDS-ODM and at each
media change. Cells were then stained with alizarin red
and imaged with bright-field microscopy (Figure 1E),
and the amount of staining was quantified by eluting
with cetylpyridinium chloride. BMSCs treated with ana-
logs 2c, 2g, and 2l demonstrated a 1.6-fold, 1.6-fold, and
1.9-fold increase in osteogenesis, respectively, relative to
vehicle-treated BMSCs (P < 0.05; Figure 1F). ASCs
treated with analogs 2c, 2g, and 2l demonstrated a simi-
lar trend and osteogenesis was enhanced by a 1.7-fold,
2.0-fold, and 2.2-fold increase, respectively, relative to
vehicle-treated ASCs (P < 0.05; Figure 1F). Furthermore,
analog 2l-treated BMSCs and ASCs demonstrated en-
hanced osteogenesis compared with E2-treated and
daidzein-treated BMSCs and ASCs (P < 0.001; Figure 1F),
suggesting that analog 2l is a more potent osteogenic
compound than E2 or daidzein.
Figure 1 Estradiol and phytoestrogens enhance osteogenic and adipogenic differentiation of bone marrow-derived mesenchymal stem
cells and adipose-derived stromal/stem cells. (A) to (D) Bone marrow-derived mesenchymal stem cells (BMSCs; n = 6) and adipose-derived
stromal/stem cells (ASCs; n = 6) were cultured in charcoal dextran-stripped osteogenic differentiation medium (CDS-ODM) or charcoal dextran-stripped
adipogenic differentiation medium (CDS-ADM) and simultaneously delivered vehicle (dimethylsulfoxide (DMSO)), 17β-estradiol (E2; 10 nM), daidzein
(1 μM), or genistein (1 μM). (A) After 14 days, cells treated with E2, daidzein, or genistein and induced with CDS-ODM were stained with alizarin red.
Scale bar represents 100 μm. (B) Stains were eluted with 10% cetylpyridinium chloride (CPC) to quantify the amount of alizarin red staining and
measured at 590 nm. Osteogenic differentiation was determined relative to vehicle-treated cells (normalized to 1.0). (C) After 14 days, cells induced
with CDS-ADM were stained with oil red O. Scale bar represents 100 μm. (D) To quantify the amount of oil red O staining, cells were eluted with
isopropanol and measured at 544 nm. Adipogenic differentiation was determined relative to vehicle-treated cells (normalized to 1.0). (E), (F) BMSCs
(n = 6) and ASCs (n = 6) were cultured in CDS-ODM and simultaneously delivered vehicle (DMSO), E2 (10 nM), daidzein (1 μM), daidzein analog 2c
(1 μM), daidzein analog 2g (1 μM), or daidzein analog 2l (1 μM). (E) After 14 days, cells induced with CDS-ODM were stained with alizarin red. Scale bar
represents 100 μm. (F) To quantify the amount of alizarin red staining in BMSCs and ASCs treated with vehicle, E2, daidzein, or daidzein analogs, cells
were eluted with 10% CPC and measured at 590 nm. Osteogenic differentiation was determined relative to vehicle-treated cells normalized to 1.0.
Bars, ± standard deviation. *P < 0.05; **P < 0.01 compared with vehicle-treated cells. ###P < 0.001 compared with E2-treated cells. ΨΨΨP < 0.001
compared with daidzein-treated cells.
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BMSCs and ASCs demonstrated enhanced osteogenic
differentiation, these compounds failed to simulate adipo-
genic differentiation. BMSCs and ASCs treated with analog
2c demonstrated adipogenic differentiation comparablewith vehicle-treated BMSCs and ASCs, while analog
2g-treated and 2l-treated BMSCs and ASCs demonstrated
a significant reduction in adipogenic differentiation com-
pared with vehicle-treated, E2-treated, or daidzein-treated
BMSCs or ASCs (P < 0.001; Additional file 2).
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ation were associated with changes caused by cytotox-
icity or increased proliferation, BMSCs and ASCs were
cultured in CCM supplemented with vehicle, daidzein
analog 2g, or daidzein analog 2l and assessed after 7 and
14 days. Analog 2g-treated and 2l-treated BMSCs dem-
onstrated similar growth rates to vehicle-treated BMSCs
(P > 0.05; Additional file 3). Likewise, 2g-treated and 2l-
treated ASCs demonstrated similar rates of proliferation
compared with vehicle-treated ASCs, as no difference
was observed in cell number after 7 or 14 days (P > 0.05;
Additional file 3).Daidzein analogs 2g and 2l have similar EC50 values but
differ in effectiveness
Additional studies were conducted to determine the con-
centration of daidzein analogs required to induce EC50 on
osteogenesis of BMSCs and ASCs in the most potent
compounds: 2g and 2l. Analogs 2g and 2l were thus ad-
ministered to BMSCs and ASCs at concentrations ranging
from 100 pM to 1 mM, at log-fold increases. The EC50
value for E2 in BMSCs and ASCs was 10-8.35 and 10-9.20,
respectively (Additional file 4). The EC50 value for daid-
zein, analog 2g, and analog 2l in BMSCs was 10-6.62, 10-6.99,
and 10-6.99, respectively (Additional file 4). The EC50 values
for daidzein, analog 2g, and analog 2l in ASCs were com-
parable with those for BMSCs: 10-7.76, 10-7.53, and 10-7.32,
respectively (Additional file 4). E2 displays the most potent
stimulation of osteogenesis in BMSCs and ASCs, leading
to enhanced osteogenesis at 1 nM to 10 nM concentra-
tions. However, analog 2l treatment at1 μM concentration
resulted in the greatest degree of osteogenic differentiation
in BMSCs (2.0-fold) and ASCs (2.4-fold; Figure 2). HigherFigure 2 Effect of daidzein analogs on osteogenic differentiation of bon
stromal/stem cells is dose dependent. (A) Bone marrow-derived mesench
cells (ASCs; n = 6) were cultured in charcoal dextran-stripped osteogenic di
17β-estradiol (E2), daidzein, or daidzein analog 2g or 2l at concentrations b
alizarin red, destained with cetylpyridinium chloride, and measured at 590 nm
cells normalized to 1.0. Bars, ± standard deviation.doses of E2 were unable to induce osteogenesis equal to
or exceeding that of analog 2l (P < 0.05; Figure 2).
Enhanced alkaline phosphatase activity and increased
phosphate deposition was observed in analog 2g-treated
and 2l-treated BMSCs and ASCs
Due to the enhanced efficacy of analogs 2g and 2l, add-
itional techniques were utilized to determine whether cells
treated with 2g or 2l enhanced early osteogenesis. BMSCs
and ASCs treated with vehicle, E2, daidzein, analog 2g, or
analog 2l for 3 days were incubated in BCIP/NBT, the sub-
strate for ALP. E2 enhanced BMSC and ASC differenti-
ation by 2.0-fold and 1.6-fold, respectively; analog 2g
enhanced differentiation by 2.1-fold and 2.4-fold; and ana-
log 2l enhanced differentiation by 1.9-fold and 2.6-fold
(P < 0.05; Figure 3A,B). While daidzein-treated BMSCs
demonstrated enhanced ALP activity (1.6-fold increase;
P < 0.05) relative to vehicle, daidzein-treated ASCs dis-
played similar ALP activity to vehicle-treated ASCs.
To assess phosphate deposition, which is secreted
during late osteogenesis and is an essential component
of the mature extracellular matrix of bone, cells were
treated with vehicle, E2, daidzein, analog 2g, or analog
2l for 14 days and incubated in silver nitrate. While E2-
treated and daidzein-treated BMSCs and ASCs demon-
strated enhanced phosphate deposition, E2 treatment
resulted in greater phosphate deposition than daidzein
treatment (P < 0.001; Figure 3C,D). Structural modifica-
tions of daidzein into analogs 2g and 2l resulted in in-
creased phosphate deposition (P < 0.001; Figure 3C,D).
Treatment of BMSCs and ASCs with analog 2l resulted
in the most significant increase in phosphate deposition
compared with all other treatment groups (P < 0.001;
Figure 3C,D).e marrow-derived mesenchymal stem cells and adipose-derived
ymal stem cells (BMSCs; n = 6) and (B) adipose-derived stromal/stem
fferentiation medium and simultaneously treated with vehicle,
etween 100 pm and 1 mM. After 14 days, cells were fixed, stained with
. Osteogenic differentiation was determined relative to vehicle-treated
Figure 3 Daidzein analogs increase alkaline phosphatase activity and phosphate deposition in bone marrow-derived mesenchymal
stem cells and adipose-derived stromal/stem cells. Bone marrow-derived mesenchymal stem cells (BMSCs; n = 6) and adipose-derived
stromal/stem cells (ASCs; n = 6) were cultured in charcoal dextran-stripped osteogenic differentiation medium and simultaneously delivered
vehicle, 17β-estradiol (E2; 10 nM), daidzein (1 μM), or daidzein analog 2g or 2l (1 μM). (A) After 3 days, cells were stained were fixed and stained
with 5-bromo-4-chloro-3-indolyl phosphate. (B) To quantify alkaline phosphatase (ALP) activity, the number of positive pixels per image (for a
total of five images/donor) was counted by Image J (Sigma, St. Louis, MO, USA). (C) After 14 days, cells were stained were fixed and stained with
silver nitrate. (D) To quantify phosphate deposition after silver nitrate staining, the number of pixels per image (for a total of five images/donor)
was counted by Image J. Images were acquired at 4× magnification. Scale bar represents 100 μm. Bars, ± standard deviation. ***P < 0.001 com-
pared with vehicle-treated cells; #P < 0.05 compared with E2-treated cells; ###P < 0.001 compared with E2-treated cells; ΨΨΨP < 0.001 compared with
daidzein-treated cells.
Strong et al. Stem Cell Research & Therapy 2014, 5:105 Page 8 of 17
http://stemcellres.com/content/5/4/105Together, these results suggest that BMSCs and ASCs
treated with E2 demonstrate enhanced osteogenesis
through increased ALP activity and phosphate deposition.
Daidzein analogs 2g and 2l also resulted in enhanced ALP
activity and phosphate deposition. Treatment with daid-
zein was less effective than treatment with E2 or daidzein
analogs.
BMSCs and ASCs treated with 17β-estradiol demonstrate
induction of early, middle, and late genes involved in
osteogenesis
While BMSCs and ASCs treated with E2 displayed simi-
lar temporal induction of early and late osteogenic
genes, significant differences were observed in the induc-
tion of middle osteogenic genes (Figures 4 and 5). More
specifically, E2 induced the expression of early osteo-
genic genes (c-FOS and COL1A1) within 3 days in both
BMSCs and ASCs (P < 0.05; Figures 4 and 5). However,
the levels of gene induction varied between BMSCs and
ASCs. Following 3 days of treatment, E2 increased c-
FOS expression by 2.4-fold in BMSCs, while E2 en-
hanced c-FOS expression by 141.1-fold in ASCs, relative
to undifferentiated cells. The induction of COL1A1 ex-
pression was different between BMSCs and ASCs: 3.4-fold in BMSCs and 18.3-fold in ASCs, relative to undif-
ferentiated cells (P < 0.05; Figures 4 and 5). These results
highlight the differences in response to E2 stimulation.
Furthermore, differences were observed in the effects
of E2 on middle osteogenic genes both temporally and
in relation to induction level. SPARC and DLX5 was up-
regulated following 7 days of E2 treatment in BMSCs,
while SPARC, DLX5, and SPP1 was upregulated follow-
ing 14 days of treatment in ASCs, relative to undifferen-
tiated cells (P < 0.05; Figures 4 and 5). E2-treated BMSCs
displayed higher levels of induction in the middle genes
on day 7, relative to undifferentiated cells (SPARC, 6.9-
fold in BMSCs vs. 1.3-fold in ASCs; DLX5, 17.8-fold in
BMSCs vs. 5.8-fold in ASCs; Figures 4 and 5).
Additional differences between BMSCs and ASCs as-
sociated with E2 stimulation were in RUNX2 and IGF1
expression. RUNX2 expression in BMSCs was increased
(9.1-fold) following 7 days of E2 treatment, while en-
hanced RUNX2 expression in ASCs (22.0-fold) did not
occur until 14 days, relative to undifferentiated cells
(P < 0.05; Figures 4 and 5). IGF1 induction was signifi-
cantly enhanced in BMSCs following E2 treatment after
3 days in BMSCs, while this effect was not observed in
ASCs (Figures 4 and 5; Additional file 5). Together, these
Figure 4 Expression of early, middle, and late-stage lineage-specific osteogenic genes in bone marrow-derived mesenchymal stem
cells was significantly induced by daidzein analogs. Bone marrow-derived mesenchymal stem cells (BMSCs) were cultured in charcoal
dextran-stripped osteogenic differentiation medium and concurrently treated with vehicle, 17β-estradiol (E2; 10 nM), daidzein (1 μM), or daidzein
analog 2g or 2l (1 μM). Cells were collected after 3, 7, or 14 days of treatment. RNA was isolated from the cells and reverse transcribed into cDNA.
Analysis of (A) early, (B) middle, or (C) late osteogenic transcription factors by quantitative polymerase chain reaction. Expression values are
normalized to undifferentiated cells normalized to 1.0. Bars, ± standard deviation. *P < 0.05 compared to vehicle-treated BMSCs; ***P < 0.001
compared with vehicle-treated BMSCs; #P < 0.05 compared with E2-treated BMSCs; ###P < 0.001 compared with E2-treated BMSCs; ΨP < 0.05 compared
with daidzein-treated BMSCs; ΨΨΨP < 0.001 compared with daidzein-treated BMSCs.
Strong et al. Stem Cell Research & Therapy 2014, 5:105 Page 9 of 17
http://stemcellres.com/content/5/4/105results suggest that E2 stimulates the expression of osteo-
genic genes in both BMSCs and ASCs.
Daidzein-treated, analog 2g-treated, and analog
2l-treated BMSCs and ASCs display different gene
expression profiles
BMSCs and ASCs were treated with daidzein and col-
lected after 3, 7, and 14 days. The expression of key
osteogenic factors was investigated by quantitative poly-
merase chain reaction. Daidzein-treated BMSCs increased
RUNX2 and SPARC expression by 9.1-fold and 3.6-fold,
respectively, relative to undifferentiated BMSCs (P < 0.05;Figure 4). Daidzein-treated ASCs demonstrated increased
c-FOS expression by 134.9-fold after 3 days, and COL1A1
and IGF1 expression by 3,899.6-fold and 10.2-fold, re-
spectively, after 14 days, compared with undifferentiated
ASCs (P < 0.001; Figure 5).
In contrast, BMSCs treated with analog 2g increased
RUNX2 expression by 7.9-fold on day 7 and COL1A1 on
days 3, 7, and 14 by 10.8-fold, 4.1-fold, and 21,600.4-fold,
respectively (P < 0.05; Figure 4). The expression of COL1A1
was significantly more robust compared with E2-treated or
daidzein-treated BMSCs on day 14 (P < 0.001; Figure 4C).
ASCs treated with analog 2g demonstrated increased
expression of COL1A1 compared with vehicle-treated,
Figure 5 Expression of early, middle, and late-stage lineage-specific osteogenic genes in adipose-derived stromal/stem cells was
significantly induced by daidzein analogs. Adipose-derived stromal/stem cells (ASCs) were cultured in charcoal dextran-stripped osteogenic
differentiation medium and concurrently treated with vehicle, 17β-estradiol (E2; 10 nM), daidzein (1 μM), or daidzein analog 2g or 2l (1 μM). Cells
were collected after 3, 7, or 14 days of treatment. RNA was isolated from the cells and reverse transcribed into cDNA. Analysis of (A) early, (B)
middle, or (C) late osteogenic transcription factors by quantitative polymerase chain reaction. Expression values are normalized to undifferentiated
cells normalized to 1.0. Bars, ± standard deviation. *P < 0.05 compared with vehicle-treated ASCs; **P < 0.01 compared with vehicle-treated ASCs;
***P < 0.001 compared with vehicle-treated ASCs; ###P < 0.001 compared to E2-treated ASCs; ΨΨΨP < 0.001 compared with daidzein-treated ASCs.
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Figure 5C).
Unlike E2, daidzein, or analog 2g, BMSCs treated with
analog 2l showed increased expression of all early, middle,
and late osteogenic genes investigated in this study. Rela-
tive to undifferentiated BMSCs, BMSCs treated with ana-
log 2l demonstrated an enhanced expression of RUNX2,
c-FOS, SPARC, DLX5, SPP1, COL1A1, and IGF1 by
152.8-fold, 51.6-fold, 34.4-fold, 41.2-fold, 38.8-fold,
31.8-fold, and 124.4-fold, respectively, on day 3 (P < 0.05;
Figure 4). Daidzein analog 2l continued to induce the ex-
pression of c-FOS, SPARC, DLX5, and SPP1 by 1.8-fold,
8.9-fold, 182.8-fold, and 12.3-fold, respectively, on day 7(P < 0.05; Figure 4). Additionally, analog 2l-treated BMSCs
displayed increased late osteogenic genes COL1A1 and
IGF1 even on day 14 (P < 0.05; Figure 4). These results
suggest that analog 2l significantly induces osteogenesis
through induction of key osteogenic regulatory genes to
initiate and maintain osteogenesis.
While the effects of analog 2l on BMSCs were pro-
nounced, the effects of analog 2l on ASCs were attenu-
ated. ASCs treated with analog 2l displayed enhanced
c-FOS expression by 204.5-fold after 3 days (P < 0.05;
Figure 5). After 14 days of differentiation, analog 2l-
treated ASCs displayed higher expression of COL1A1
(4,139.8-fold) compared with vehicle-treated (1,471.7-fold)
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Likewise, analog 2l-treated ASCs demonstrated enhanced
IGF-1expression (22.6-fold) after 14 days, compared with
vehicle-treated ASCs (6.8-fold) or E2-treated ASCs (4.4-
fold; P < 0.05; Figure 5).
Fulvestrant reversed the osteogenic effects of daidzein
and analog 2g while only attenuating the effects of
analog 2l
To determine the estrogenic activity of daidzein, ER in-
hibitor studies were performed on BMSCs and ASCs by
treating cells simultaneously with daidzein and fulves-
trant. Fulvestrant reduced the osteogenic potential of
daidzein-treated BMSCs and ASCs from 1.7-fold to 1.0-
fold and from 1.5-fold to 1.0-fold, respectively (Figure 6).
While daidzein increased the expression of RUNX2 on
day 7, simultaneous treatment with fulvestrant reducedFigure 6 Fulvestrant treatment reduces osteogenic induction by daid
osteogenic transcription. Bone marrow-derived mesenchymal stem cells
charcoal dextran-stripped osteogenic differentiation medium (CDS-ODM) a
(1 μM), or daidzein analog 2g or 2l (1 μM) and fulvestrant. After 14 days, (A
cetylpyridinium chloride (CPC). Quantification of the stain was measured at
ASCs were collected after 3, 7, or 14 days of treatment. RNA was isolated fr
transcription factors were assessed by quantitative polymerase chain reacti
1.0. Bars, ± standard deviation. *P < 0.05 compared with fulvestrant-treated
compared with fulvestrant-treated cells; ###P < 0.001 compared with fulvest
daidzein-treated cells.RUNX2 expression by 56.0%, from 3.0-fold to 1.3-fold
(P < 0.05; Figures 4 and 6; Additional files 6 and 7). With
respect to ASCs, concomitant fulvestrant treatment re-
duced daidzein-induced c-FOS expression by 66.7% on
day 3 (from 1.5-fold to 0.5-fold; P < 0.001), IGF1 by
85.7% on day 7 (from 2.8-fold to 0.4-fold; P < 0.01), and
COL1A1 by 42.3% on day 14 (from 2.6-fold to 1.5-fold;
P < 0.05; Figures 4 and 6; Additional files 5, 7 and 8).
These inhibitor studies suggest that daidzein works through
an ER-dependent mechanism as fulvestrant treatment re-
duced expression of genes activated by daidzein.
To investigate the activation of ER signaling pathways
by analog 2g, inhibitor studies were conducted with
BMSCs and ASCs by simultaneously treating cells with
analog 2g and fulvestrant in CDS-ODM for 3, 7, or
14 days. Fulvestrant treatment reduced the osteogenic
activity of analog 2g in BMSCs and ASCs to levelszein analogs through inhibition of early, middle, and/or late
(BMSCs) or adipose-derived stromal/stem cells (ASCs) were cultured in
nd concurrently treated with vehicle, 17β-estradiol (E2; 10 nM), daidzein
) BMSCs and (C) ASCs were stained with alizarin red and eluted with
590 nm and normalized to vehicle-treated cells. (B) BMSCs and (D)
om the cells and reverse transcribed into cDNA. Analyses of osteogenic
on. Expression values are normalized to undifferentiated cells set to
cells; **P < 0.01 compared with fulvestrant-treated cells;***P < 0.001
rant and E2-treated cells; ΨΨΨP < 0.001 compared with fulvestrant and
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to 0.8-fold and from 2.0-fold to 0.9-fold, respectively
(P < 0.001; Figure 6). Furthermore, BMSCs treated with
analog 2g and fulvestrant displayed reduced RUNX2
expression by 79.0% (from 4.3-fold to 0.9-fold) on day 3,
COL1A1 expression by 91.6% (from 10.8-fold to 0.9-fold)
on day 3, and IGF1 expression by 97.8% (from 40.9-fold to
0.9-fold) on day 7 (P < 0.05; Additional files 5, 6 and 7).
With respect to ASCs, fulvestrant inhibited the activity
of analog 2g by reducing RUNX2 expression on day 7 by
65.1% (from 6.3-fold to 2.2-fold) and COL1A1 expression
on day 14 by 75% (from 4.4-fold to 1.1-fold; P < 0.01;
Additional files 7, 8 and 9). Together, these results in-
dicate that analog 2g acts through an ER-mediated
mechanism, with reduced activity in the presence of
fulvestrant.
Furthermore, to determine the estrogenic activity of
analog 2l, concomitant treatment of 2l with fulvestrant
resulted in reduced osteogenesis in BMSCs and ASCs.
Osteogenic differentiation was not completely inhibited
by fulvestrant, suggesting that analog 2l-induced osteo-
genic differentiation is through both ER-dependent and
ER-independent pathways. Simultaneous delivery of ful-
vestrant with analog 2l reduced the osteogenesis of
BMSCs (2.0-fold to 1.5-fold) and ASCs (2.4-fold to 1.7-fold;
P < 0.001; Figure 6). Furthermore, fulvestrant reduced the
expression of early and middle osteogenic genes in both
BMSCs and ASCs, suggesting that the estrogenic mechan-
ism of fulvestrant on osteogenesis is through the induction
of early to middle osteogenic genes. COL1A1 and IGF1
expression remained induced in BMSCs even in the
presence of fulvestrant (Figure 6; Additional files 2 and 9),
suggesting that analog 2l utilizes an alternative non-ER-
driven pathway to induce osteogenesis. Lastly, due to the
impact of analog 2l on late osteogenic genes COL1A1 and
IGF1, analysis of additional late osteogenic genes was con-
ducted. Treatment with analog 2l increased DMP1 (3.9-
fold) and SOST (2.2-fold) expression in BMSCs, while 2l
had no effect on DMP1 or SOST expression in ASCs
(Additional file 10). In BMSCs, fulvestrant treatment re-
versed the increased expression in SOST by analog 2l but
did not alter DMP1 expression (Additional file 10). These
data suggest that analog 2l selectively induces osteogenesis
through non-ER-dependent mechanisms that result in the
upregulation of COL1A1, IGF1, and SOST in BMSCs and
of COLA1A and IGF1 in ASCs.
Discussion
Osteoporosis is a disease characterized by decreasing
BMD and a loss of the bone architecture, resulting in in-
creased fragility and fracture incidence. To reduce the
progression of the disease and increase bone strength,
the development of new compounds to increase osteo-
genesis is necessary. In this study, synthetic daidzeinanalogs have been tested for their in vitro osteogenic poten-
tial in both BMSCs and ASCs. Daidzein analogs 2g and 2l
were found to increase osteogenic differentiation character-
ized by alizarin red staining, ALP activity, and silver nitrate
staining. In addition, these daidzein analogs enhanced
osteogenic differentiation of BMSCs and ASCs relative to
E2-treated or daidzein-treated cells. Furthermore, simul-
taneous treatment with fulvestrant eliminated the osteo-
genic activity of daidzein analog 2g and attenuated the
osteogenic activity of analog 2l, suggesting that 2g acts
predominantly through ER signaling while 2l may use
both ER-dependent and ER-independent pathways. Ana-
lysis of transcript levels of key osteogenic genes showed
that analogs 2g and 2l differentially induced osteogenic
genes in BMSCs and ASCs. These results raise the poten-
tial that individual daidzein analogs may function through
distinct ER signaling mechanisms such as ERα, ERβ or the
G-protein-coupled ER. Recent research has demonstrated
the involvement of G-protein-coupled ER as a mechanism
of rapid ER signaling that can cross-talk with classic ER
mechanisms or function in a distinct manner [25-27]. A
combination of ERα/β-mediated and G-protein-coupled
ER-mediated mechanisms may thus exist by which daid-
zein analogs influence the MSC and ASC differentiation
responses. Evidence has also demonstrated that fulvestrant
alone exhibits effects on gene expression apart from its
anti-estrogenic effects, which further supports the possi-
bility that certain daidzein analogs may function through dis-
tinct G-protein-coupled ER-dependent or ER-independent
pathways [28-30].
Consistent with previously published studies, genistein
and daidzein increased the osteogenic potential of BMSCs
and ASCs. Previous work by Bitto and colleagues demon-
strated that genistein enhanced the BMD but also restored
structure to ovariectomy-induced osteoporotic bone in
rats [31,32]. Furthermore, the effects of genistein treat-
ment in rats improved the overall architecture and
strength of the bone better than raloxifene, a commonly
used selective ER modulator used to treat osteoporosis
[31,32]. Comparative studies have shown that daidzein is
more effective than genistein in preventing ovariectomy-
induced bone loss in rats [33]. Indeed, daidzein was shown
to enhance BMD in lumbar vertebrae, femur, and in the
metaphyseal and diaphyseal zones, which have been
shown to be rich in cancellous and cortical bone, respect-
ively [33]. Daidzein treatment has also been shown to
increase biomechanical strength by increasing collagen
formation, while reducing osteoclast activity to limit the
amount of degradation to the extracellular matrix [34,35].
Together, daidzein treatment leads to reduced resorptive
activity and increased anabolic activity in bone. The re-
sults of this study provide additional support for the ana-
bolic activity of daidzein in BMSCs and ASCs. Additional
studies have shown that daidzein with high calcium
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multiple sites in an ovariectomized mouse model [36],
providing for the supplementation of daidzein with
current osteoporosis treatment regimes.
While these phytoestrogens have proven effective in in-
creasing bone density in rodent models, novel daidzein
derivatives developed by our group were tested on BMSCs
and ASCs to determine their potential to enhance bone
differentiation and regeneration. Studies have shown that
derivatives of genistein and daidzein have yielded better
outcomes as anti-osteoporotic compounds compared with
their original forms, either increasing anabolic activity or
decreasing resorption activity. Wang and colleagues dem-
onstrated that genistein derivatives act as potential select-
ive ER modulators and increased the weight of bone in
the femur relative to no treatment or treatment with ge-
nistein [37]. Other soy derivatives have been shown to in-
crease in vitro osteoblast maturation in primary cultures
of rat calvarial osteoblasts, to stimulate the differentiation
of osteoblasts, and to increase the transcript levels of osteo-
genic genes involved in differentiation and mineralization
[38]. Yadav and colleagues reported that modifying the
two hydroxyl groups into alkoxy groups could lead to syn-
thetic daidzein derivatives with altered potency [39]. One
such compound, 7-(2-diethylamino-ethoxy)-3-(4-methoxy-
phenyl)-4H-chromen-4-one, increased mineralization of
bone marrow osteoprogenitor cells and increased mRNA
expression of bone morphogenetic protein-2 and osteocal-
cin [39]. Our approach only modified the 7-hydroxy moiety
by substituting the hydrogen with an isopropyl (daidzein
analog 2c), a cyclopentyl (daidzein analog 2g), or an allyl
(daidzein analog 2l) while retaining the 4-hydroxy moiety,
rather than modifying both hydroxyl groups. We have
previously studied the effect of such structural modifica-
tions on the estrogenic activity of daidzein analogs and
demonstrated the sensitivity of 7-hydroxy substitution to
the agonist/antagonist propensity of the daidzein deriva-
tives [21]. While all three analogs have lower estrogenic
activity than daidzein [21,22], the specific alkyl substitu-
tion of the 7-hydroxy hydrogen yielded significantly in-
creased osteogenic activity. Higher dosages of compounds
2g and 2l in our study did not negatively impact the osteo-
genic activity of the cells, nor lead to cytotoxicity. Add-
itional studies of structure–activity relationships are
underway in our laboratories to determine whether
further structural alterations at the other sites will pro-
vide increased potency and/or maintain the enhanced
efficacy that has been gained by modifications of the 7-
hydroxy moiety.
Furthermore, previous studies have also attributed the
osteogenic effects of daidzein to the production of equol
in the gut. Our previous study thus focused on structurally
modifying daidzein to generate equol analogs and investi-
gated whether the equol structural motif conferred greaterosteogenic potency [20]. However, our results suggested
that the daidzein analogs investigated in this paper, 2g and
2l, demonstrated greater osteogenic activity than the equol
analogs. Additional equol analogs are being prepared in
our laboratory, which may provide more definitive evi-
dence for enhance osteogenic activity compared with the
equol analogs investigated previously.
Although analog 2g possessed much weaker estrogenic
activity than E2, 2g treatment enhanced RUNX2, SPARC,
and IGF1 in BMSCs and enhanced RUNX2 and COL1A1
in ASCs. RUNX2 is essential for osteoblast development
and proper bone formation, regulating transcription of
numerous genes that control osteoblast development from
mesenchymal stem cells and maturation [40,41]. SPARC,
IGF1, and COL1A1 have all been implicated in increasing
BMD, increasing biomechanical strength, and maintaining
the extracellular matrix [42]. The inhibitory effect of ful-
vestrant on the osteogenic activity of analog 2g-treated
BMSCs and ASCs provide additional support for the es-
trogenic activity of 2g, suggesting that the weaker analog
2g appears to enhance osteogenic activity through signal-
ing pathways associated with ER.
Likewise, structural modification of daidzein into ana-
log 2l also enhanced osteogenic differentiation of BMSCs
and ASCs, possibly through ER pathways. Interestingly,
unlike analog 2g, fulvestrant treatment did not abolish
the osteogenic activity of analog 2l, suggesting that 2l is
likely to be acting through an ER-independent mechan-
ism. To confirm this finding, the downstream effect of
analog 2l on BMSCs and ASCs were explored in this
study. The molecule targeted by analog 2l will probably
converge with the identification of key downstream osteo-
genic genes identified here. BMSCs and ASCs treated with
analog 2l demonstrated alterations in the transcriptional
level of select early, middle, and late osteogenic genes
involved in differentiation of the cells and mineralization
of the extracellular matrix. In BMSCs treated with analog
2l, all osteogenic genes were upregulated, suggesting a
powerful effect of 2l on BMSCs. In contrast, ASCs treated
with analog 2l demonstrated a less pronounced effect, al-
tering only c-FOS, COL1A1, and IGF1 [43].
While our study focused on osteogenic activity of the
daidzein analogs, it should be noted that the daidzein
analogs reduced adipogenic differentiation at 1 μM con-
centration. While our treatment of genistein and daid-
zein did not yield significant reduction in BMSCs and
ASC adipogenic differentiation, it is possible that the
dosage used was not adequate to see an effect. Kim and
colleagues determined that a 20 μM concentration was
necessary to reduce adipogenic differentiation of ASCs,
and higher concentrations resulted in greater inhibition
[44]. Delivery of daidzein also reduced body weight in
obesity-induced animals and reduced the expression of
adipogenic genes in a dose-dependent manner [44-46].
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have likewise been effective in treating high-fat diet-
induced male obese mice [47]. These previous studies, in
conjunction with our current study, would suggest fur-
ther investigating the use of daidzein analogs to reduce
diet-induced obesity, as these analogs were more potent
than daidzein.
To our knowledge, this study is the first to examine
the effects of genistein or daidzein on bone differentiation
in human ASCs. Our study demonstrated that these com-
pounds have similar effects on ASCs as on BMSCs. Our
study of daidzein analogs further shows that minor struc-
tural modifications of daidzein further increased the
osteogenic differentiation of BMSCs and ASCs, although
the effect was more pronounced in ASCs. Both BMSCs
and ASCs are derived from the same germ layer and as
such possess similar biologic characteristics. However, in-
depth analysis of these two cell types has recently revealed
differences in immunophenotypical and gene expression
profiles [48-50]. Monaco and colleagues determined that
ASCs have larger lipid metabolism, migration, and immu-
nomodulatory capacity during early osteogenic differenti-
ation compared with BMSCs, while BMSCs have larger
induction of inflammation, cell growth, and proliferation
[48]. Consistent with previous reports, our study suggests
that differences exist between BMSCs and ASCs which
may account for the differences in the transcript levels of
osteogenic genes following induction by daidzein analogs.
More specifically, BMSCs and ASCs treated with the same
daidzein analog express different mRNA levels of osteo-
genic factors. Furthermore, recent studies have combined
the availability of ASCs and their osteogenic differenti-
ation for tissue engineering [51]. ASCs and BMSCs have
been seeded onto extracellular matrix scaffolds to increase
bone formation [52]. The daidzein analogs investigated in
this study could be coated onto these scaffolds to deter-
mine their in vivo efficacy in future experiments.
Lastly, as these compounds would be used in postmeno-
pausal women, it is important for these compounds to
have no effect on breast cancer and endometrial cancer.
Theoretically, a drug used to treat osteoporosis should in-
crease BMD without increasing the risk of cancer. An im-
portant advantage of the daidzein analogs compounds is
the limited estrogenic effect of these compounds on can-
cer cells. Previous studies have determined that daidzein
and daidzein derivatives have negligible effects on cancer
growth or progression [21,53-57]. As such, it is possible
that these compounds could be used in combination with
chemotherapy or other forms of cancer therapy to reduce
the incidence of osteoporosis in at-risk patients. Further-
more, these compounds could be used in combination
with other anti-osteoporotic drugs to reduce osteoporosis
[58]. However, additional in vivo analyses of these com-
pounds in osteoporosis-induced ovariectomized mice orrats or in critical-sized calvarial defect models are neces-
sary to determine the regenerative potential of these com-
pounds as well as to determine the pharmacokinetics of
these compounds for potential combination therapy.Conclusion
Osteoporosis is a debilitating disease associated with re-
duced BMD, increased incidence of fractures, poor mo-
bility, and increased morbidity and mortality. While
current therapeutic interventions have been focused on
anti-resorptive drugs, development of anabolic drugs that
increase bone regeneration is necessary to compensate for
bone loss during osteoporosis. In this study, the use of
synthetic daidzein derivatives was investigated for the in-
duction of in vitro osteogenesis in BMSCs and ASCs and
provided potential mechanisms of action of these com-
pounds. While these data provide a foundation for further
analyses of the daidzein analogs in BMSCs or ASCs,
in vitro or in vivo, future studies are necessary to investigate
the role of these compounds in a rodent ovariectomized
model of osteoporosis on BMD and bone architecture and
for the translation of these compounds clinically to improve
the outcomes of patients diagnosed with osteoporosis.Additional files
Additional file 1: Shows a characterization of BMSCs and ASCs.
BMSCs (n = 6) and ASCs (n = 6) were each induced to undergo
osteogenic and adipogenic differentiation, immunophenotyped for cell
surface antigens with flow cytometry, and the colony formation potential
determined. (A) BMSCs and ASCs were cultured in ODM or ADM for
14 days and stained with alizarin red or oil red O, respectively.
Representative images of osteogenesis (4× magnification) and
adipogenesis (10× magnification) in BMSCs and ASCs are shown. Scale
bar represents 200 μm. (B) Cells were stained with cell surface markers,
CD44, CD90, CD106, CD166, CD11b, CD34, and CD45 and their respective
isotype controls. Each overlay contains the isotype control for each cell
type and the cell surface marker of interest. (C) BMSCs and ASCs were
plated at 100 cells per 10 cm plate and were stained with crystal violet
after 14 days in culture to visualize the colony-forming units.
Additional file 2: Shows daidzein analogs inhibit adipogenesis.
BMSCs (n = 6) and ASCs (n = 6) were each induced to undergo
adipogenic differentiation and treated with vehicle, E2, daidzein, or
daidzein analog (1 μM) for 14 days and stained with oil red O. (A)
Representative images of cells stained with oil red O are shown at 10×
magnification. Scale bar represents 100 μm. (B) To quantify the amount
of oil red O staining in treated BMSCs and ASCs, cells were eluted with
isopropanol and measured at 544 nm. Adipogenic differentiation was
determined relative to vehicle-treated cells (normalized to 1.0). Bars, ± standard
deviation. *P< 0.05; **P< 0.01; ***P< 0.001.
Additional file 3: Shows analogs 2g and 2l do not demonstrate
cytotoxic or proliferative effects on BMSCs and ASCs. (A) BMSCs
(n = 6) and (B) ASCs (n = 6) were each cultured in CCM supplemented
with vehicle or daidzein analog (1 μM) for 7 or 14 days and assessed by
MTT assay. Bars, ± standard deviation.
Additional file 4: Presents the EC50 of each compound in BMSCs
and ASCs. Values presented in molar (M) concentration.
Additional file 5: Presents the gene expression profile of BMSCs
and ASCs treated with E2, daidzein, analog 2g, analog or 2l in the
presence and absence of fulvestrant on day 3. Data normalized to
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to the respective vehicle-treated cells.
Additional file 6: Shows that ER antagonist fulvestrant inhibits the
expression of osteogenic genes induced by daidzein analogs in
BMSCs. BMSCs were cultured in CDS-ODM and concurrently treated with
vehicle, E2 (10 nM), daidzein (1 μM), or daidzein analog (1 μM) and ER
antagonist fulvestrant. Cells were collected after 3, 7, or 14 days of
treatment. RNA was isolated from the cells and reverse transcribed into
cDNA. Analyses of osteogenic genes were assessed by quantitative polymerase
chain reaction. Expression values are normalized to undifferentiated cells,
normalized to 1.0. Bars, ± standard deviation.
Additional file 7: Presents the gene expression profile of BMSCs
and ASCs treated with E2, daidzein, analog 2g, or analog 2l in the
presence and absence of fulvestrant on day 7. Data normalized to
vehicle-treated cells after 7 days. *P < 0.05; **P < 0.01; ***P < 0.001 relative
to the respective vehicle-treated cells.
Additional file 8: Presents the gene expression profile of BMSCs
and ASCs treated with E2, daidzein, analog 2g, or analog 2l in the
presence and absence of fulvestrant on day 14. Data normalized to
vehicle-treated cells after 14 days. *P < 0.05; **P < 0.01; ***P < 0.001
relative to the respective vehicle-treated cells.
Additional file 9: Shows that fulvestrant-treated ASCs demonstrate
reduced expression of osteogenic transcription factors induced by
daidzein analogs. ASCs were cultured in CDS-ODM and concurrently
treated with vehicle, E2 (10 nM), daidzein (1 μM), or daidzein analog
(1 μM) and ER antagonist fulvestrant (100 nM). Cells were collected after
3, 7, or 14 days of treatment. RNA was isolated from the cells and reverse
transcribed into cDNA. Analyses of osteogenic genes were assessed by
quantitative polymerase chain reaction. Expression values are normalized
to undifferentiated vehicle-treated cells, normalized to 1.0. Bars, ± standard
deviation. *P < 0.05; **P < 0.01; ***P < 0.001 relative to vehicle-treated cells.
Additional file 10: Presents the gene expression profile of BMSCs
and ASCs treated with analog 2l in the presence and absence of
fulvestrant on day 14. Data normalized to vehicle-treated cells after
14 days. *P < 0.05; relative to the respective vehicle-treated cells.Abbreviations
ALP: alkaline phosphatase; ASC: adipose-derived stromal/stem cell; BCIP/
NBT: 5-bromo-4-chloro-3-indolyl phosphate; BMD: bone mineral density;
BMSC: bone marrow-derived mesenchymal stem cell; CCM: complete culture
media; CDS-ADM: charcoal dextran-stripped adipogenic differentiation
medium; CDS-ODM: charcoal dextran-stripped osteogenic differentiation
medium; c-FOS: FBJ murine osteosarcoma viral oncogene homolog;
CO2: carbon dioxide; COL1A1: collagen type 1 alpha; DLX5: distal-less
homeobox 5; DMP1: dentin matrix acidic phosphoprotein 1; E2: 17β-
estradiol; EC50: half-maximal effective concentration; EDTA: ethylenediamine
tetraacetic acid; ER: estrogen receptor; IGF1: insulin-like growth factor 1;
ODM: osteogenic differentiation medium; PBS: phosphate-buffered saline;
RUNX2: runt-related transcription factor 2; SOST: sclerostin;
SPARC: osteonectin; SPP1: secreted phosphoprotein 1.Competing interests
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